This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Martoma Is 79th Conviction In Feds' Insider Trading Sideshow (Update 1)

Updated from 3:42 p.m. ET with changes throughout.

NEW YORK ( TheStreet) --Former SAC Capital Advisors portfolio manager Matthew Martoma Thursday became the latest insider trading conviction as federal prosecutors continue to do their best in the wake of the financial crisis to show taxpayers how tough they are on Wall Street, while hopefully padding their resumes in the process.

Martoma, 39, got two doctors to give him privileged information tied to an experimental drug to treat Alzheimers being developed by Elan Corp. and Wyeth Pharmaceuticals. Elan was acquired by Perrigo (PRGO) last year and Wyeth was bought by Pfizer (PFE) in 2009.

After Martoma learned the drugs weren't ready to market, SAC sold Elan and Wyeth shares and took short positions, avoiding losses and earning $275 million, according to news reports.

The conviction by a Manhattan federal jury on one count of conspiracy and two counts of securities fraud could lead to up to 20 years in prison for Martoma. It is part of a roughly 10-year investigation of Steven A. Cohen and his hedge fund SAC Capital Advisors.

Cohen has so far avoided criminal charges, though SAC pled guilty to insider trading in November and was forced to stop managing money for outside investors. Cohen also faces civil charges brought by the Securities and Exchange Commission for failing to adequately supervise his employees. Still, he continues managing a $9 billion "family office."

The conviction is the 79th for the Manhattan U.S. attorney's office as party of a multi-year insider trading crackdown. It hasn't yet lost a case.

Still, rather than typing up another rave review for U.S. Southern District Attorney Preet Bharara, who has overseen the insider trading sweep, I'd prefer to cite Gary Aguirre, an iconoclastic former SEC attorney who got drummed out of the Securities and Exchange Commision for pushing too hard on an insider trading case involving former Morgan Stanley (MS - Get Report) and Credit Suisse (CS - Get Report) CEO John Mack. (Aguirre later won a large wrongful termination settlement and was vindicated by a Senate Investigation.)

Referring to the inside trading crackdown in the August issue of Wall Street Lawyer, Aguirre wrote, "this huge commitment of resources over the past six years comes with a cost, perhaps too high. Resources are finite. Allocating those resources to insider trading cases obviously means those resources are unavailable to investigate and prosecute those responsible for the 2008 financial crisis. That crisis brought the U.S. and the world to their knees. Insider trading was not a cause of that crisis."

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CS $24.34 0.00%
MS $35.79 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs